Kathryn Kilroy, Author at Synspire Pharmaceuticals - Page 2 of 3

Synspire Pharmaceuticals Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis

Posted on October 11, 2018May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals Receives U.S. FDA Orphan Designation for SNSP113 for the Treatment of Cystic Fibrosis”

Synspire Pharmaceuticals PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells

Posted on August 9, 2018May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals PAAG Therapy Demonstrates Persistence Against Pseudomonas aeruginosa Persister Cells”

In vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus

Posted on August 3, 2018May 11, 2023 by Kathryn Kilroy

Synedgen Announces Publication of Study Exploring the Role of Biological Ions in Controlling Mucosal Surfaces

Posted on January 31, 2018October 30, 2018 by Kathryn Kilroy

Read on Synedgen

Bloomberg: Shenda Baker PhD discusses Synspira on Boston radio

Posted on January 17, 2018October 30, 2018 by Kathryn Kilroy

Listen on Bloomberg (minutes 41-58)

Novel glycopolymer eradicates antibiotic- and CCCP- induced persister cells in Pseudomonas aeruginosa

Posted on January 17, 2018May 11, 2023 by Kathryn Kilroy

Synspire Pharmaceuticals Novel Glycopolymer Proves Effective Against Antibiotic Resistance

Posted on January 17, 2018May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals Novel Glycopolymer Proves Effective Against Antibiotic Resistance”

Synspire Pharmaceuticals Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference

Posted on November 2, 2017May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals Announces Data for Lead Candidate at the 31st Annual North American Cystic Fibrosis Conference”

Synspire Pharmaceuticals Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis

Posted on October 18, 2017May 10, 2023 by Kathryn Kilroy

Continue reading “Synspire Pharmaceuticals Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis”

Cystic Fibrosis News Today: Synspira’s Therapy Candidate May Be a Game-Changer for Drug-Resistant Bacteria in CF

Posted on July 31, 2017October 30, 2018 by Kathryn Kilroy

Read on Cystic Fibrosis News Today